Literature DB >> 12704055

Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results.

Christian Loewe1, Martin Schindl, Manfred Cejna, Bruno Niederle, Johannes Lammer, Siegfried Thurnher.   

Abstract

OBJECTIVE: The purpose of our study was to assess the results of hepatic artery embolization using N-butyl-2-cyanoacrylate and ethiodized oil for the treatment of small-bowel neuroendocrine metastases to the liver as part of a multimodality protocol for the treatment of liver metastases from neuroendocrine small-bowel tumors.
MATERIALS AND METHODS: Twenty-three patients underwent permanent embolization of the hepatic artery using cyanoacrylate and Lipiodol for treatment of liver metastases after radical resection of small-bowel neuroendocrine tumors. All patients received additional treatment including somatostatin, and most patients received interferon as well. Cumulative survival rates were estimated using the Kaplan-Meier method.
RESULTS: Overall, 75 embolizations (range, 1-10; mean, 3.3) were performed. Median survival time was 69 months, and the estimated cumulative survival rates reached 95.7% and 65.4% for 1 and 5 years, respectively. Two deaths (8.7%) occurred within 1 month of treatment, and one patient experienced a vascular complication at the time of embolization.
CONCLUSION: Permanent embolization of hepatic arteries as part of a multimodality treatment protocol is beneficial in long-term follow-up for patients with metastasized small-bowel neuroendocrine tumors. The use of cyanoacrylate as an embolic agent is safe and effective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704055     DOI: 10.2214/ajr.180.5.1801379

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  27 in total

Review 1.  Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.

Authors:  Thomas J Vogl; Stephan Zangos; Katrin Eichler; Danny Yakoub; Mohamed Nabil
Journal:  Eur Radiol       Date:  2006-08-30       Impact factor: 5.315

2.  A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Authors:  J R Strosberg; J M Weber; J Choi; T L Campos; T L Valone; G Han; M J Schell; L K Kvols
Journal:  Ann Oncol       Date:  2012-02-08       Impact factor: 32.976

3.  Acute thrombocytopenia: An uncommon complication occurring following transarterial chemoembolization in a patient with neuroendocrine hepatic metastases.

Authors:  Pingkun Xie; Zheng Yuan
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

Review 4.  Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Authors:  Magaly Zappa; Mohamed Abdel-Rehim; Olivia Hentic; Marie-Pierre Vullierme; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Target Oncol       Date:  2012-05-22       Impact factor: 4.493

5.  Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.

Authors:  Francesco Fiore; Michela Del Prete; Renato Franco; Vincenzo Marotta; Valeria Ramundo; Francesca Marciello; Antonella Di Sarno; Anna Chiara Carratù; Chiara de Luca di Roseto; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-01-03       Impact factor: 3.633

6.  Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.

Authors:  Khairuddin Memon; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Vanessa L Gates; Bassel Atassi; Steven Newman; Reed A Omary; Al B Benson; Riad Salem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

7.  Minute liver metastases from a rectal carcinoid: A case report and review.

Authors:  Hirofumi Yamamoto; Hideyuki Hemmi; Jin-Yu Gu; Mitsugu Sekimoto; Yuichiro Doki; Masaki Mori
Journal:  World J Gastrointest Surg       Date:  2010-03-27

Review 8.  Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.

Authors:  Sanjay Gupta
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

9.  Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors.

Authors:  D Gomez; H Z Malik; A Al-Mukthar; K V Menon; G J Toogood; J P A Lodge; K R Prasad
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 10.  Evolving treatment strategies for management of carcinoid tumors.

Authors:  Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.